At Zoomtopia 2026, Zoom Video Communications announced an enhanced deployment of Zoom Clinical Notes, an ambient artificial ...

RELATIVITY-047's 5-year survival data and LAG-3-high CD8+ T cell biomarker findings signal a shift in how immuno-oncology ...

IMA402 PRAME bispecific continues to demonstrate encouraging anti-tumor activity in multiple indications, alongside a ...

Limited ("Alebund" or the "Company"; HKEX: 09637), a renal-focused biopharmaceutical company, today announced that its partner, R1 Therapeutics, Inc. ("R1"), presented a trial-in-progress poster ...

Syneos Health and Optum have announced a partnership to build what they describe as a more adaptive and connected model for ...

New Report puts the market at $66.3bn in 2025, with oncology accounting for 38.3% and North America just over half, though patchy insurer coverage and infrastructural barriers remain stubborn ...

Following my previous post, I have been thinking about the current state of AI drug discovery. In the first part, I defined ...

A retrospective FSGS biopsy cohort found that heterogeneous TRPC5 staining was associated with poor treatment response and ...

Technology can strengthen global clinical development, but it cannot compensate for limitations embedded in trial design. Asia's opportunity extends beyond increasing clinical-trial volume or ...

A genomic and phenotypic screen of 95 clinical isolates shows that strong biofilm producers of Nakaseomyces glabratus cluster ...

Financial News] ABL Bio Inc. is releasing clinical data on two bispecific immuno-oncology drug candidates and accelerating ...

Two offline clinical reference tools lead a lineup of 14 medical study and reference apps with no ads, accounts or ...